U.S. markets closed

Apyx Medical Corporation (APYX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.21-0.05 (-0.54%)
At close: 4:00PM EDT
9.21 0.00 (0.00%)
After hours: 04:00PM EDT
Sign in to post a message.
  • j
    jackson
    Can anyone explain why apyx has been dropping the last few days?
  • Y
    Yahoo Finance Insights
    Apyx Medical is up 5.66% to 9.61
  • M
    Matt
    Following the recent completion of our U.S. IDE clinical study evaluating the use of our Renuvion technology in dermal resurfacing procedures, we were pleased to submit our 510(k) premarket notification for this procedure category on May 28th,” said Charlie Goodwin, President and Chief Executive Officer. “This submission is an important milestone that underscores our continued progress in pursuing specific clinical indications to market and sell Renuvion for target procedures in the cosmetic surgery market.
  • M
    Matt
    Nice day yesterday, hope we’re in for more of the same TODAY!
  • M
    Matt
    ODD! Market down BIG And APYX is up???
    Bullish
  • Y
    Yahoo Finance Insights
    Apyx Medical is up 5.30% to 9.94
  • J
    J
    Apyx Medical Corporation
    FLASH NOTE
    June 19, 2019

    Kyle Bauser, Ph.D.
    (612) 376-4191 kbauser@doughertymarkets.com
    Rating: Buy
    Price: $6.79 | Price Target: $10.00
    Reason for Report: Company Update
    Investor Meetings with Management; APYX Shares Still Undervalued; Reiterate Buy Rating

    Key Points:
    We had the opportunity this week to host investor meetings with APYX CEO Charlie Goodwin and Director Craig Swandal. We remain buyers of APYX shares given the company's 1) addressable market, 2) balance sheet, 3) confidence in subsequent trial designs & outcomes, and 4) new focus on Renuvion following the divestiture of the core business last year. Despite strength in the stock since the April selloff, we believe there is still significant upside, particularly as we learn more about the company's regulatory and commercial activities.
  • s
    steve
    Any of you guys got a view on whether the certification is merely postponed or as good as canned? It looks like the share price has found a floor for the moment but I don't understand what that floor is based on.
  • M
    Matt
    Daugherty investments raised their price target from $11 to $12.
  • B
    Bikerider79
    While other companies with coherent and competent leadership are issuing updates (whether they are an essential business, whether they are open, updating guidance, what they are doing financially to make it through the crisis, etc.), Apyx is completely silent. This is unforgivable, but not surprising considering the track record of this woeful management.
  • s
    steve
    This stock is all over the place - can't recall such a divergent set of views, Glad I am in on a negative share price having been a long term BVX holder and trader. Will be a buyer below 6 and seller above 9.5 - unless I hear a more consistent message.
  • M
    Matt
    This will be a $30+ stock in a year.
    Bullish
  • S
    Superbowl6
    If we finish the day on the up tick at the close I think we will recover a lot of todays loss tomorrow.
    I can't find anything negative and in fact Fidelity has APYX rated at a "10" out of a possible "10". there is no higher rating.
  • M
    Matt
    Apyx Medical Corporation
    FLASH NOTE
    February 22, 2019

    Kyle Bauser, Ph.D.
    (612) 376-4191 kbauser@doughertymarkets.com
    Rating: Buy
    Price: $6.40 | Price Target: $11.00
    Reason for Report: Company Update
    We Are Aggressive Buyers Following Short Report

    Key Points:
    Yesterday a report was published that made several false claims against APYX. We believe the selloff was excessive, are aggressive buyers today, and remind investors of the following:
    The results of the wrinkle removal clinical study, which were part of the FDA 510(k) application, will be released after FDA clearance (as we've mentioned). We do not believe that if the trial results were poor, CEO Goodwin would have decided to sell off the Core business two months after the final patient was enrolled last May. Additionally, waiting to announce results prevents unnecessary off-label conversations.
    Since J-Plasma/Renuvion isn't yet approved for use to remove wrinkles (dermal resurfacing), there is not a set protocol for off-label use of the device. Any off-label use by a practitioner is therefore at their discretion. Once APYX achieves approval for this indication, the company will be able to train physicians on proper patient screening and treatment protocol.
    CEO Goodwin was not named as a defendant in the Olympus DOJ case. He was mentioned in the documents, but the extent of his interaction with the DOJ was one interview without a lawyer present and delivery of his laptop. After speaking with the DOJ, CEO Goodwin remained at Olympus for another 2.5 years. No charges were brought against him personally.
    CEO Goodwin has transformed a slow generator business into a high-growth cosmetic medtech company in one year. The company now has more than 5 years of cash on hand to support a device that's growing 64%. We believe he has been very forthcoming and transparent with the current strength of the business and the direction in which he intends to take the company.
    The report calls out ELOS, SLTM, and CUTR as good comps, but the corresponding growth rates for these companies were/are 5%, -4%, and 6% – these pale in comparison to APYX sales growth of 64%. Additionally, APYX's gross margin last quarter was 69% vs. the "comps" of 53%, 57%, and 54%.
    $530K in General Payments by the company is in-line with medtech comps. This is part of the Sunshine Act and payments were spent on physician training. We analyzed the small cap medtech space (47 publicly traded companies sub $1B mkt cap) and found the average amount of General Payments to be $582K in 2017 (or $882K if only considering companies that allocated funding towards this activity).
    J-Plasma is currently being used on-label for subdermal coagulation following liposuction. This falls within the general indication "cutting and coagulation of soft tissue during both open and laparoscopic surgical procedures." With respect to this indication, we estimate there to be 400,000 liposuction procedures per year in the US. (Per ASAPS, liposuction procedures grew 16.5% in 2017 to 305K, which implies 414K procedures in 2019.) We believe 20% of cosmetic surgeons do 80% of the total volume, which equates to 107 liposuction procedures per year per high volume doc (320,000 procedures / 3,000 physicians). If we assume doctors add J-Plasma to a liposuction procedure for an extra $1,500, then extra profits would be $825 (net of ASP and extra procedure time), or $88K on an annual basis. The average high volume doc would therefore be able to pay off the capital equipment ($85,000 ASP) within 12 months, which is in line with feedback we are hearing from users.
    No patient or cosmetic surgeon ever said the dermal resurfacing procedure would be easy. Cosmetic surgeons use J-Plasma to essentially burn off the top layer of the skin. Patients are well aware of the risk ahead of the cosmetic procedure, but there is always the chance of poor outcomes, particularly when doctors use a device off-label without a standardized treatment protocol. There aren't many cosmetic device companies that don't have claims reported in the MAUDE database.
    Last month Apyx preannounced impressive 4Q18 sales results. Management expects 4Q18 sales to be between $5.9M-$6.1M vs. our previous estimate of $5.2M and previous guidance of $5.0M-$5.4M. Management guided Advanced Energy (J-Plasma) sales to $4.4M-$4.5M and OEM sales to $1.5M-$1.6M. The revised guidance implies 45% Y/Y growth in Advanced Energy (AE) and 170% growth in OEM. The company will release 4Q18 results after the markets close on March 13th and host a conference call at 4:30pm ET (US: 844-507-6493; OUS: 647-253-8641; ID: 5488443).
    Valuation. We reiterate our Buy rating and $11 Price Target, which assumes an 8.0x EV/CY20E sales multiple (similar to peers) applied to $41.8M CY20E sales, $74.9M net cash, and 37.6M fully diluted shares outstanding
  • n
    norman
    It was 2 months ago that I warned that we would get another nice profit (50% my guess ) because of bikerider
    sending us another buy signal . Look back at the stock price 2 months ago and my forecast of another nice
    gain from the usual bull from APYX haters . I still ask we give the management the fourth quarter to prove
    we are on track and then APYX holders can vote on how the company performed . Be patient all .
    Neutral
  • M
    Matt
    On it’s way to $30 - $40. Hold on for the ride!
    Bullish
  • w
    wehlan
    Look at RCG (RENN) ownes 600,000 shares and is selling below book value as a closed end fund. Easy way to pick up cheap shares.
  • M
    Matt
    Latest issued price target $14.
    40% upside!
  • J
    J
    Bike rider won a couple of battles but ultimately lost the war.
  • G
    Grazyna
    Does anyone have any idea why the stock went down today?